474 completed, 55 terminated, 43 unknown, 18 withdrawn. 205 Phase 1, 167 Phase 2, 110 Phase 3, 89 Phase 4, 38 Not applicable.
Follow Ritonavir: new trials by email Literature Review of Ritonavir trials Research Report on Ritonavir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Adaptive Platform Trial for Evaluation of Novel Treatment Regimens in Children and Adolescents With HIV in Africa Dolutegravir (DTG), Abacavir (ABC), Lamivudine (3TC) - HIV Infection | Phase 3 | Not yet recruiting | University College, London | 800 | 2026-11-01 | 2026-08-28 |
| STARLITE for Unresectable High-Grade Gliomas Magnetic Resonance (MR)-guided Laser Interstitial Thermal Therapy (LITT), Abacavir, Lamivudine - High Grade Glioma | Phase 1 | Recruiting | University of Miami | 24 | 2025-04-15 | 2026-06-25 |
| Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer SHR-A1811, Ritonavir, Itraconazole - Advanced Breast Cancer | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 17 | 2025-02-17 | 2026-06-04 |
| Clinical Trial of Gammora® Plus Antiretroviral Treatment for HIV Gammora® - HIV Seropositivity | Phase 2 | Active not recruiting | Federal University of São Paulo | 40 | 2025-01-01 | 2026-06-01 |
| Extended Remdesivir Infusion Combined With Nirmatrelvir/Ritonavir for Persistent SARS-CoV-2 Infection in Immunocompromised Patients combination therapy, SOC - COVID-19, SARS-CoV-2 | Not applicable | Not yet recruiting | National Taiwan University Hospital | 40 | 2024-09-21 | 2024-09-25 |
| A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments F/TAF (High Dose Tablet), F/TAF (Low Dose Tablet), F/TAF (Lowest Dose Tablet) - HIV-1-infection | Phase 4 | Recruiting | Gilead Sciences | 350 | 2024-08-27 | 2026-11-06 |
| A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors DB-1311, Lopinavir and Ritonavir Tablets, itraconazole - Advanced Solid Tumors | Phase 1 / Phase 2 | Recruiting | DualityBio Inc. | 862 | 2023-08-17 | 2026-10-21 |
| RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms Paxlovid, Ritonavir, Nirmatrelvir-matching placebo - Long COVID-19, Long COVID | Phase 2 | Completed | Kanecia Obie Zimmerman | 964 | 2023-07-26 | 2026-03-27 |
| Drug-Drug Interaction Study of Itraconazole With GST-HG171/Ritonavir in Healthy Participants GST-HG171/Ritonavir, Itraconazole - Healthy Participant | Phase 1 | Completed | Fujian Akeylink Biotechnology Co., Ltd. | 12 | 2023-05-12 | 2023-10-17 |
| Food Effects of GST-HG171 Tablets Combined With Ritonavir in Healthy Chinese Participants GST-HG171/ritonavir, ritonavir - COVID-19 Respiratory Infection | Phase 1 | Unknown | Fujian Akeylink Biotechnology Co., Ltd. | 18 | 2023-05-04 | 2023-10-16 |
| ImPROving Quality of LIFe in the Long COVID Patient Nirmatrelvir/ritonavir, Placebo/ritonavir - Post-COVID-19 Syndrome, Long COVID | Phase 2 | Completed | Karolinska Institutet | 219 | 2023-05-01 | 2024-12-04 |
| OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial Paxlovid 5 days, Paxlovid 10 days, Veklury - COVID-19, Immunodeficiency | Phase 2 | Recruiting | ANRS, Emerging Infectious Diseases | 256 | 2023-04-27 | 2026-10-19 |
| A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults with Long COVID. Nirmatrelvir, Ritonavir, Placebo - Long COVID | Phase 2 | Completed | Harlan M Krumholz | 100 | 2023-04-14 | 2024-12-02 |
| Safety and Pharmacokinetics of SIM0417 Combined With Ritonavir in Healthy Elderly Subjects SIM0417/Ritonavir - Elder | Phase 1 | Unknown | Jiangsu Simcere Pharmaceutical Co., Ltd. | 20 | 2023-04-07 | 2023-04-24 |
| A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients Relugolix Pill, Ritonavir, Itraconazole - Prostate Cancer, Prostate Cancer Metastatic | Phase 1 | Terminated | University of Chicago | 60 | 2023-02-13 | 2024-09-19 |
| Study to Evaluate Safety, Tolerability, PK and the Food Effect on PK of ASC11/RTV Tablets in Healthy Subjects ASC11 tablets, Placebo, RTV tablets - Healthy, COVID-19 | Phase 1 | Completed | Ascletis Pharmaceuticals Co., Ltd. | 72 | 2023-01-13 | 2024-11-13 |
| Drug-Drug Interaction Study of Itraconazole, Rifampicin and Midazolam With SIM0417/Ritonavir in Healthy Participants Cohort 1: SIM0417/ritonavir and itraconazole, Cohort 2: SIM0417/ritonavir and rifampicin, Cohort 3: SIM0417/ritonavir and midazolam - Healthy Volunteers | Phase 1 | Completed | Jiangsu Simcere Pharmaceutical Co., Ltd. | 36 | 2022-12-29 | 2023-02-21 |
| Study of GST-HG171/Ritonavir Compared With Placebo in Patients With Mild to Moderate COVID-19 GST-HG171/Ritonavir, Placebo - COVID-19 Pneumonia | Phase 2 / Phase 3 | Completed | Fujian Akeylink Biotechnology Co., Ltd. | 1246 | 2022-12-19 | 2023-10-12 |
| A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19 Nirmatrelvir, Ritonavir, Placebo for nirmatrelvir - Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19) | Phase 2 | Withdrawn | Pfizer | 2022-12-13 | 2023-03-01 | |
| A Study to Learn About the Medicine (PF-07321332 or Nirmatrelvir/Ritonavir) in Healthy Lactating Women nirmatrelvir, ritonavir - Healthy Participants | Phase 1 | Completed | Pfizer | 8 | 2022-12-12 | 2026-05-01 |
Showing 20 of 604. Sign in to see all of them.
HIV Infections (251) · Acquired Immunodeficiency Syndrome (89) · Hepatitis C (40) · COVID-19 (39) · Infections (30) · Hepatitis C, Chronic (26) · Tuberculosis (8) · Coronavirus Infections (7) · Lipodystrophy (5) · Severe Acute Respiratory Syndrome (5) · Virus Diseases (5) · Breast Feeding (4) · Carcinoma, Non-Small-Cell Lung (4) · Hepatitis D (4) · Immunologic Deficiency Syndromes (4)
Boehringer Ingelheim (56) · National Institute of Allergy and Infectious Diseases (NIAID) (48) · Hoffmann-La Roche (35) · ViiV Healthcare (26) · Bristol-Myers Squibb (23) · Abbott (19) · GlaxoSmithKline (16) · Pfizer (15) · Merck Sharp & Dohme LLC (13) · Gilead Sciences (12) · Tibotec Pharmaceuticals, Ireland (12) · ANRS, Emerging Infectious Diseases (11) · The HIV Netherlands Australia Thailand Research Collaboration (11) · French National Agency for Research on AIDS and Viral Hepatitis (10) · AbbVie (9)
United States (273) · Spain (67) · Puerto Rico (63) · France (60) · United Kingdom (56) · Germany (54) · Italy (47) · Canada (43) · Thailand (38) · Brazil (32) · South Africa (32) · Argentina (31) · China (28) · Belgium (26) · Australia (24)
Huoling Tang, PhD (5) · Kiat Ruxrungtham, MD (5) · Mikhail Samsonov (5) · Daniel Cohen, MD (3)
PMID 40592258, PMID 33901188, PMID 34473343, PMID 37231296, PMID 15687448, PMID 16148846, PMID 18090046, PMID 20074791, PMID 25109510, PMID 25904376, PMID 26797215, PMID 26902761, PMID 29767684, PMID 35179037, PMID 37354048, PMID 10659875, PMID 10954886, PMID 11023461, PMID 11372025, PMID 11399973, PMID 11840078, PMID 11880966, PMID 11927734, PMID 11964551, PMID 11980557, PMID 12195349, PMID 14668455, PMID 14668456, PMID 15002082, PMID 15031785, PMID 15060509, PMID 15090769, PMID 15097312, PMID 15155205, PMID 15187476, PMID 15199325, PMID 15295692, PMID 15316349, PMID 15456093, PMID 15483465, PMID 15668539, PMID 15958837, PMID 16048950, PMID 16048984, PMID 16084849, PMID 16091248, PMID 16103764, PMID 16159645, PMID 16192247, PMID 16220085
2014 (12), 2009 (11), U01AI068636 (7), 2008 (4), 2015 (2), 2023 (2), K23AI074390 (2), 2004 (1), 2005 (1), 2017 (1), 2019 (1), K23AI070078 (1), K23AI077355 (1), K23AI093156 (1), R01AI083036 (1)